Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 19;14(6):2101.
doi: 10.3390/jcm14062101.

Kidney Transplant: More than Immunological Problems

Affiliations
Review

Kidney Transplant: More than Immunological Problems

Rosana Gelpi et al. J Clin Med. .

Abstract

Kidney transplantation (KT) represents a pivotal intervention for patients with chronic kidney disease (CKD), significantly improving survival and quality of life. However, KT recipients face an array of non-immunological complications, collectively amplifying cardiovascular (CV) and metabolic risks. This review explores the intersection of cardio-metabolic syndrome and KT, emphasizing the recently introduced cardiovascular-kidney-metabolic (CKM) syndrome. CKM syndrome integrates metabolic risk factors, CKD, and CV disease, with KT recipients uniquely predisposed due to immunosuppressive therapies and pre-existing CKD-related risks. Key issues include post-transplant hypertension, obesity, dyslipidemia, post-transplant diabetes mellitus (PTDM), and anemia. Immunosuppressive agents such as corticosteroids, calcineurin inhibitors, and mTOR inhibitors contribute significantly to these complications, exacerbating metabolic dysfunction, insulin resistance, and lipid abnormalities. For instance, corticosteroids and calcineurin inhibitors heighten the risk of PTDM, while mTOR inhibitors are strongly associated with dyslipidemia. These pharmacologic effects underscore the need for tailored immunosuppressive strategies. The management of these conditions requires a multifaceted approach, including lifestyle interventions, pharmacological therapies like SGLT2 inhibitors and GLP-1 receptor agonists, and close monitoring. Additionally, emerging therapies hold promise in addressing metabolic complications in KT recipients. Proactive risk stratification and early intervention are essential to mitigating CKM syndrome and improving outcomes. This comprehensive review highlights the importance of integrating cardio-metabolic considerations into KT management, offering insights into optimizing long-term recipient health and graft survival.

Keywords: cardio-metabolic syndrome; cardiovascular risk; chronic kidney disease; dyslipidemia; hypertension; kidney transplantation; post-transplant anemia; post-transplant diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Lee Y.H., Song S.H., Song S.H., Shin H.S., Yang J., Kim M.S., Hwang H.S. Clinical implications of changes in metabolic syndrome status after kidney transplantation: A nationwide prospective cohort study. Nephrol. Dial. Transplant. 2023;38:2743–2753. doi: 10.1093/ndt/gfad115. - DOI - PubMed
    1. Ndumele C.E., Rangaswami J., Chow S.L., Neeland I.J., Tuttle K.R., Khan S.S., Coresh J., Mathew R., Baker-Smith C., Carnethon M.R., et al. American Heart Association.Cardiovascular-kidney-metabolic health: A Presidential advisory from the American Heart Association. Circulation. 2023;148:1606–1635. doi: 10.1161/CIR.0000000000001184. - DOI - PubMed
    1. Cases A., Broseta J.J., Marqués M., Cigarráne S., Julián J.C., Alcazar R., Ortiz A. La definición del síndrome cardiovascular-reno-metabólico (cardiovascular-kidney-metabolic syndrome) y su papel en la prevención, estatificación del riesgo y tratamiento. Una oportunidad para la Nefrología. Nefrologia. 2024;44:771–783. doi: 10.1016/j.nefro.2024.05.001. - DOI - PubMed
    1. Teresa V.S., Domingo H.M. Complicaciones Cardiovasculares en el Trasplante Renal. In: Lorenzo V., López Gómez J.M., editors. Nefrología al día. Elsevier; Amsterdam, The Netherlands: 2022.
    1. Mancia G., Kreutz R., Brunström M., Burnier M., Grassi G., Januszewicz A., Muiesan M.L., Tsioufis K., Agabiti-Rosei E., Algharably E., et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA) J. Hypertens. 2023;41:1874–2071. - PubMed

LinkOut - more resources